Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Metabolic Disorder Drugs Market Global Briefing 2017

Metabolic Disorder Drugs Market Global Briefing 2017

From $1,000.00

Including: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Covering: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG


Clear selection
SKU: 2276. Categories: , .
Description

North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA. Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.

Metabolic Disorder Drugs Market Global Briefing from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.

The market characteristics section of the report defines and explains the market.

The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.

Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.

The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches.

Reasons to Purchase

• Get up to date information available on the metabolic disorder drugs market globally.
• Identify growth segments and opportunities.
• Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
• Develop strategies based on likely future developments.
• Gain a global perspective on the development of the market.

 

Scope

Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

 

Executive Summary
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.

The global metabolic disorder drugs market is expected to reach around $110 billion in 2020. The market is expected to be driven by rapid growth in diabetic patients which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030.

Development Of New Anti-Diabetic Drugs For Type 2 Diabetes – Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin. In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients. Similarly, in April 2017, scientists from the Central Drug Research Institute (CDRI) in India had found that chalcone, a plant-derived substance, can be used to produce an anti-diabetic drug that can improve insulin sensitivity and reduce blood glucose levels in patients with type-2 diabetes.
Table of Contents
Metabolic Disorder Drugs Market Characteristics 5
Metabolic Disorder Drugs Market Historic Growth 7
Metabolic Disorder Drugs Market Forecast Growth 8
Metabolic Disorder Drugs Market Segmentation 9
Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion 9
Anti-diabetics Drugs 10
Anti-thyroid drugs 10
Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 10
Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segments, 2012-2020 11
Metabolic Disorder Drugs Market Geography Regional and Country Comparison 13
Global Metabolic Disorder Drugs Market, Split By Regions, 2016 13
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Global Metabolic Disorder Drugs Market, Split By Country, 2016 17
Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Metabolic Disorder Drugs Market Competitive Landscape 21
Sanofi S.A. 22
Novo Nordisk A/S 22
AstraZeneca Plc. 22
Johnson & Johnson 22
Merck & Co. 22
Abbott Laboratories Inc. 22
Boehringer Ingelheim GmbH 22
Pfizer Inc. 22
AbbVie Inc. 22
Takeda Pharmaceuticals 22
Sanofi 23
Novo Nordisk 23
AstraZeneca PLC 24
Metabolic Disorders Drugs Market Key Mergers And Acquisitions 25
Alexion Acquired Synageva 25
AstraZeneca Acquired ZS Pharma 25
Horizon Pharma Plc. Acquired Hyperion Therapeutics, Inc. 25
Horizon Pharma Plc. Acquired Raptor Pharmaceutical Corp. 25
Madrigal Pharmaceuticals Merged With Synta Pharmaceuticals Corp. 25
Metabolic Disorders Drugs Market Trends And Strategies 26
Development Of New Anti-Diabetic Drugs For Type 2 Diabetes 26
Enzyme Replacement Therapies For The Treatment Of Of Rare Metabolic Disorders 26
Increase In Mergers And Acquisitions 26
Appendix 27
NAICS Definitions Of Industry Covered In This Report 27
Definition Of Market Covered In This Report 27
The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. 27
Abbreviations 27
Currencies 27
Research Methodology 27
Research Inquiries 28
The Business Research Company 29

List of Figures
Figure 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Figure 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Figure 3: Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion 9
Figure 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 11
Figure 5: Global Metabolic Disorder Drugs Market, Split By Region, 2016, $ Billion 13
Figure 6: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Figure 7: Global Metabolic Disorder Drugs Market, Split By Country, 2016, $ Billion 17
Figure 8: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Figure 9: Global Metabolic Disorder Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 21

List of Tables
Table 1: Global Metabolic Disorder Drugs Market, Historic Market Size, 2012-2016, $ Billion 7
Table 2: Global Metabolic Disorder Drugs Market, Forecast Market Size, 2016 – 2020, $ Billion 8
Table 3: Global Metabolic Disorder Drugs Market, Split By Segments, 2016, $ Billion 9
Table 4: Global Metabolic Disorder Drugs Market, Historic and Forecast, Split By Segment, 2012 – 2020 11
Table 5: Global Metabolic Disorder Drugs Market, Split By Region, 2016, $ Billion 14
Table 6: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Region, 2012-2020 15
Table 7: Global Metabolic Disorder Drugs Market, Split By Country, 2016, $ Billion 17
Table 8: Global Metabolic Disorder Drugs Market, Historic And Forecast Growth Rate, Split By Country, 2012-2020 19
Table 9: Global Metabolic Disorder Drugs Market, Key Competitor Market Shares, 2016, Percentage (%) 22
Get Customized Report
Please fill in your details. Our team will get back to you